Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Up 5.5% Today

What is Thermo Fisher Scientific Inc?

Thermo Fisher Scientific Inc. (TMO) is a global leader in scientific services, with a focus on advanced drug development solutions and expanding its presence in the life sciences sector. The company revealed a bold 7% annual growth target at its 2026 Investor Day, demonstrating its ambitions for future growth.

Why is Thermo Fisher Scientific Inc going up?

TMO stock is up 5.5% on May 28, 2026 13:51

• The recent bullish movement in TMO's stock can be linked to its target of achieving a 7% organic revenue compound annual growth rate (CAGR) as disclosed at its recent Investor Day, indicating strong growth potential and investor support.
• While there are concerns about the sustainability of long-term growth, TMO's strategic actions, including the launch of a new bioanalytical and biomarker laboratory in Sweden, underscore its dedication to meeting market needs and strengthening its industry position.
• The announcement of a quarterly cash dividend of $0.47 per common share showcases TMO's financial stability and commitment to shareholders, fostering positive investor sentiment.
• Despite the allure of alternative opportunities in AI stocks for potentially higher short-term returns, TMO's focus on long-term growth and strategic investments positions it well for continued success in the life sciences sector.

TMO Price Chart

TMO Technical Analysis

TMO News

Is Thermo Fisher Scientific Inc. (TMO) a Buy as RBC Restarts Coverage With Sector Perform Rating?

RBC Capital has restarted coverage of Thermo Fisher Scientific Inc. (TMO) with a Sector Perform rating and a $490 price objective, citing improving market conditions but concerns about long-term growth sustainability. Concurrently, Thermo Fisher Scientific launched a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, to meet increasing demand for advanced drug development solutions and strengthen its global network. The company is a global leader in scientific services, though the article suggests that some AI stocks may offer higher returns in a shorter timeframe.

https://www.insidermonkey.com/blog/is-thermo-fisher-scientific-inc-tmo-a-buy-as-rbc-restarts-coverage-with-sector-perform-rating-1770052/

Thermo Fisher (TMO) Sets a Bold 7% Annual Growth Target at Its 2026 Investor Day

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a bold target of 7% organic revenue CAGR at its 2026 Investor Day, signifying a strong ambition for growth given its 1% organic revenue growth in Q1 2026. The company also reinforced its position as a dominant partner for life sciences customers and declared a quarterly cash dividend of $0.47 per common share. While acknowledging TMO's potential, the article suggests that certain AI stocks might offer greater upside and less downside risk.

https://finance.yahoo.com/sectors/healthcare/articles/thermo-fisher-tmo-sets-bold-215521533.html

Thermo Fisher (TMO) Sets a Bold 7% Annual Growth Target at Its 2026 Investor Day

Thermo Fisher Scientific Inc. (TMO) hosted its annual Investor Day, targeting a bold 7% organic revenue CAGR over the long term, a significant increase from its recent 1% Q1 2026 organic growth. The company emphasized its dominant position in life sciences and declared a quarterly cash dividend of $0.47 per common share. While TMO is considered a strong investment, the article suggests other AI stocks might offer greater upside potential.

https://uk.finance.yahoo.com/news/thermo-fisher-tmo-sets-bold-215521533.html

Thermo Fisher (TMO) Sets a Bold 7% Annual Growth Target at Its 2026 Investor Day

Thermo Fisher Scientific (NYSE: TMO) recently held its annual Investor Day where CEO Marc N. Casper announced a long-term goal of 7% organic revenue compound annual growth rate (CAGR). This ambitious target follows a 1% organic revenue growth in Q1 2026, with total revenue increasing by 6% due to acquisitions and favorable currency. The company also declared a quarterly cash dividend of $0.47 per common share, payable on July 15.

https://www.insidermonkey.com/blog/thermo-fisher-tmo-sets-a-bold-7-annual-growth-target-at-its-2026-investor-day-1769164/

[144] THERMO FISHER SCIENTIFIC INC. SEC Filing

Thermo Fisher Scientific Inc. (TMO) has filed a Form 144 Notice of Proposed Sale of Securities with the SEC. The filing indicates a proposed sale of 14,300 common shares with an aggregate market value of $6,465,589.08, acquired on May 27, 2026, via an option granted by the issuer on September 9, 2020. No securities were reported sold during the past three months by the person for whose account the securities are to be sold.

https://www.stocktitan.net/sec-filings/TMO/144-thermo-fisher-scientific-inc-sec-filing-e1ac196c344e.html

Trending Today

NASDAQ-100 ($NDX) Index Forecast: Up 0.5% Today

Robert Half Inc. ($RHI) Stock Forecast: Up 5.9% Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 3.4% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Up 2.9% Today

Dollar General Corporation ($DG) Stock Forecast: Up 5.0% Today

Aave ($AAVE) Crypto Forecast: Down 6.7% Today

Waters Corporation ($WAT) Stock Forecast: Up 5.5% Today

W.W. Grainger Inc. ($GWW) Stock Forecast: Up 0.6% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 1.8% Today

Novo Nordisk A/S ($NVO) Stock Forecast: Up 1.6% Today

Thermo Fisher Scientific Inc Price History

29.00.2026 - TMO Stock was down 5.2%

• Thermo Fisher (TMO) experienced a bearish movement despite reporting better-than-expected Q4 CY2025 results, with revenue surpassing analyst estimates and strong performance in its Life Sciences Solutions segment.
• The stock might have faced downward pressure due to profit-taking by investors following the immediate stock increase post-earnings report.
• The overall market sentiment could have been influenced by broader market conditions or sector rotation, leading to the bearish movement in TMO's stock price today.
• It's possible that investors were expecting even stronger guidance or future outlook from the company, causing some disappointment and resulting in the bearish market movement.

23.03.2026 - TMO Stock was down 10.0%

• Thermo Fisher's stock experienced a bearish movement despite beating first-quarter earnings estimates, primarily due to concerns over modest organic growth and a cautious outlook.
• The company's reliance on acquisitions for revenue growth, with organic growth at only 1%, raised investor worries about sustainable future growth prospects.
• The CEO's optimistic comments about benefiting from domestic manufacturing efforts and strategic collaborations were overshadowed by the market's focus on underlying growth challenges and revenue outlook concerns.
• The bearish trend might have been further exacerbated by profit-taking behavior following the recent stock repurchases and dividend increase, as investors reevaluated the company's overall growth trajectory.

23.03.2026 - TMO Stock was down 11.0%

• Thermo Fisher Scientific reported strong first-quarter results with revenue and earnings growth, driven by acquisitions and new product launches.
• Despite beating earnings estimates, the stock experienced a bearish movement due to concerns over modest organic growth and a cautious full-year revenue outlook.
• Investors focused on the company's reliance on acquisitions for revenue increase and the slightly below-consensus full-year revenue guidance, leading to the stock decline.
• The market reaction suggests that while the company's financials are solid, concerns about future organic growth and demand are weighing on investor sentiment, resulting in the bearish movement of the stock.

23.03.2026 - TMO Stock was down 10.5%

• Thermo Fisher Scientific's stock saw a bearish trend due to weaker-than-expected organic growth, which raised concerns about demand despite exceeding revenue and EPS expectations.
• The market reacted negatively to the company's reliance on acquisitions for growth, with organic revenue growth at only 1%, indicating a preference for sustainable core business performance.
• Despite successful capital deployment, new product launches, and strategic partnerships, investors prioritized the quality of underlying business growth over the earnings beat, leading to the stock decline.
• The bearish movement highlights the market's emphasis on sustainable growth and operational excellence rather than short-term financial metrics, impacting Thermo Fisher's stock performance negatively.

02.00.2026 - TMO Stock was up 2.2%

• The global single-use bioprocessing products market is expected to witness substantial growth, with Thermo Fisher Scientific Inc. playing a significant role in the industry's advancement, contributing to the optimistic market trends.
• Noteworthy increases in stakes by Allspring Global Investments Holdings LLC and Ninety One UK Ltd in TMO reflect a growing confidence in the company's future, potentially influencing a rise in the stock's value.
• Despite recent significant insider sales, the company's impressive quarterly earnings report surpassing expectations, coupled with the initiation of a new stock buyback program and quarterly dividend declaration, have likely bolstered investor trust in TMO.
• The collective institutional interest and portfolio adjustments by different investment entities indicate a favorable outlook for TMO, aligning with the current bullish market movement.

18.11.2025 - TMO Stock was down 2.4%

• The decline in TMO stock may be linked to profit-taking by institutional investors actively trading the stock.
• Despite positive updates on strong quarterly earnings and a $5 billion share buyback program, concerns arose among investors due to insider selling by the CEO and COO, potentially contributing to the stock's downward trend.
• Weak performance by West Pharmaceutical Services (WST) in the healthcare sector could have also impacted investor sentiment towards TMO, as some may have shifted away from underperforming healthcare stocks.
• In sum, today's bearish movement in TMO stock seems influenced by profit-taking, insider selling concerns, and broader sector trends affecting investor outlook.

12.01.2026 - TMO Stock was down 5.2%

• Varma Mutual Pension Insurance Co and Cornerstone Investment Partners LLC increased their holdings in TMO, showing confidence in the company's future prospects.
• ING Groep NV and Atria Investments Inc reduced their stakes in TMO, possibly due to profit-taking or portfolio rebalancing.
• The initiation of a $5 billion stock repurchase plan by Thermo Fisher Scientific may have influenced market sentiment, signaling management's belief in the company's undervaluation.
• Despite the mixed institutional activity and insider sales, analysts maintain a "Moderate Buy" rating for TMO, with an average price target of $633.68, reflecting positive quarterly earnings and growth potential.

14.03.2026 - TMO Stock was up 5.0%

• Thermo Fisher Scientific's stock surged 3.6% today, indicating a bullish trend.
• The collaboration with HealthVerity to enhance real-world data capabilities shows the company's commitment to advancing clinical research and evidence generation.
• The undervaluation of TMO compared to its GF Value™ and the strong GF Score™ of 88 highlight positive performance metrics despite insider selling, signaling potential challenges ahead.
• The focus on precision medicine growth through collaborations like PRECISE-SG100K biobank positions TMO well for long-term success in the evolving healthcare landscape.

28.04.2026 - TMO Stock was up 5.5%

• The recent bullish movement in TMO's stock can be linked to its target of achieving a 7% organic revenue compound annual growth rate (CAGR) as disclosed at its recent Investor Day, indicating strong growth potential and investor support.
• While there are concerns about the sustainability of long-term growth, TMO's strategic actions, including the launch of a new bioanalytical and biomarker laboratory in Sweden, underscore its dedication to meeting market needs and strengthening its industry position.
• The announcement of a quarterly cash dividend of $0.47 per common share showcases TMO's financial stability and commitment to shareholders, fostering positive investor sentiment.
• Despite the allure of alternative opportunities in AI stocks for potentially higher short-term returns, TMO's focus on long-term growth and strategic investments positions it well for continued success in the life sciences sector.